Aim: we investigatedthe frequency of expression of HOXA9 gene in adult Egyptian acute myeloid leukemia (AML) patients and its relation to different cytogenetic abnormalities. Methods: 30 newly diagnosed AML patients (group 1) were the subject of our study. Ten healthy persons of matched age and sex were considered group ll (controls). Estimation of HOXA9 expression in AML blasts by RT-PCR was done to both groups. Results: Normal cytogenetic analysis was present in 20 cases (66.6%), t(15,17) in 3 cases, t(8,21) in 3 cases, 45 xy -7 in 1 case, t(16,16) in 1 case, 45 xy-20 in 1 case and 46 XX 1P+ in 1 case. NUP 98 -HOXA 9 gene was not detected in any of the studied case or in the control group. Conclusion: absence of HOXA9 gene in our randomly selected patientsmay be related to its rarity in Egyptian population. However, further studies including larger population is still needed to confirm this finding with special stress on poor cytogenetic group
for body patterning during development, and for post-developmental regulatory functions. Aberrant HOX gene expression initiates leukemias.
2,3 HOXA9 particularly is important in leukemia by suppressing differentiation and maintaining self-renewal during myelopoiesis. 4 HOXA9 expression is predominant in myeloid neoplasias. 5 In addition, HOXA9has been identified as the most reliable predictor of disease outcome. 3, 5 Aim of the Work We aimed at investigating the frequency of expression of HOXA9 gene, and its relation to different cytogenetic abnormalities in adult Egyptian AML patients.
METHODS

Patients
This study was performed on 30 newly diagnosed AML patients randomly selected from the Hematology Unit at Alexandria Main University hospital in Egypt.Their age ranged from 18-56 years. 17 patients were males and 13 were females. Based on cytogenetic analysis, 6 patients were categorized into: favorable group (7 patients), intermediate group (22 patients) and unfavorable group (1 patient). The study also included 10 healthy persons of matched age and sex and they were considered group ll (controls).
INTRODUCTION
Acute myeloid leukemia (AML) is a genetically heterogeneous disorder characterized by the somatic acquisition of genetic and epigenetic alterations in hematopoietic progenitor cells that disturb normal mechanisms of self-renewal, proliferation and differentiation. In recent years, there has been increasing translation of genetic diagnostics into the clinical setting.
1
In the current World Health Organization classification, more than half of AML cases are categorized on the basis of their underlying genetic defect. Furthermore, cytogenetic and molecular genetic changes have been shown to be among the most powerful prognostic markers. Finally, novel therapies are being developed that target some of these genetic and epigenetic changes. All patients in this study were subjected to: thorough history taking and detailed clinical examination, routine investigations including complete blood picture, bone marrow aspiration, immune-phenotyping, cytochemical staining (myeloperoxidase and Sudan black B), cytogenetic analysis byG-banding 7 and estimation of HOXA9 expression in AML blasts by RT-PCR. 8 Estimation of HOXA9 expression in AML blasts by RT-PCR Total RNA was extracted from whole blood EDTA samples using the E.Z.N.A RNA extraction Kit(Omega, bio-tek) (according to manufacturer's instructions).
For RT-PCR: The master mix RT-PCR beads kit which combines cDNA synthesis from RNA with PCR amplification was used. The following primer set was used: Forward primer: TGTGGTTCTCCTCCAGTTGATAGA Reverse primer: TCGGTGAGGTTGAGCAGTCGAG, which amplifies a fragment of 267 bp for human HOXA9. 
RESULTS
Cytogenetic analysis:
Normal cytogenetic was present in 20/30 cases (66.6%). t(15,17) was present in 3 cases, t(8,21) in 3 cases, 45 xy -7 in 1 case, t (16, 16) Relation between response to chemotherapy and cytogenetic pattern: 22/30 patients were categorized as intermediate risk category.20/22 patients (90.9%) of them had normal cytogenetic.Among those with normal cytogenetic, 11/20 patients(55%) had achieved completeremission, 4 patients attained partial remission while 3 patients were refractory to chemotherapy ( Table 1) . 2 patients died before receiving chemotherapy.
DISCUSSION
There is difference in the apparent oncogenecity of HOXA genes in myeloid and lymphoid compartments.It had been suggested that the transcriptional effects of HOX genes are strongly modulated by the spectrum of DNAbinding partnerspresent in a particular lineage. Perhaps, lineage specific patterns of chromatin structure, could also affect the accessibility of HOX proteins to some genomic regions.
9,10
HOXA9gene was expressed significantly more frequently in myeloid cell lines than in lymphoid cell lines 11 . That is why we selected to study acute myeloid leukaemia rather than acute lymphoblastic leukaemia. NUP 98-HOXA 9 gene was not detected in any of our studied patients orcontrol group.A previous study examined the expression of the HOXA cluster genes (HOXA9, HOXA10, and HOXA11) in leukemic cell lines by RT-PCR. 11 The HOXA9, HOXA10, and HOXA11genes were expressed in 12 of 16 (75.0%), 14 of 16 (87.5%) and 14 of 16 (87.5%) myeloid lineage cell lines. 11 The absence of NUP 98-HOXA 9 gene expression in all our patients maybe attributed to the absence of translocation t(7;11)(p15;p15) in our studied cases. There aresome morphological features associated with t(7;11)(p15;p15), including predominantly the AML-M2 subtype with trilineage myelodysplastic features. 12, 13 AML-M2 was present in seven cases (23.33%) in our study. No dysplastic feature was detected in any case. Inthe translocation t (7;11), the NUP98gene (11p15.4), is fused to the class-1 homeobox gene HOXA9 (7p15) 14 . The NUP98gene (11p15.4) codes for a component of the nuclear pore complex that regulates nucleo-cytoplasmic transport of RNA and proteins.
14 At least two mechanisms for Nup98-HOXA9 leukemogenesis can be proposed; 1) interference with nuclear transport, e.g. preventing nuclear import of transcription factors critical for myeloid differentiation, or interference with the export of RNAs needed for myeloid differentiation, 2) aberrant transcription. Nup98-HOXA9 may cause leukemia by interfering with the transcriptional programs of hematopoietic differentiation and proliferation 13 . Splicing in Hox gene is also assigned to play a central task in Hox gene mediated leukaemogenesis. 15 As regards cytogenetics, 20 cases in our study had normal cytogenetics (66.6%), and 10 cases had cytogenetic abnormalities (33.3%). The numerical abnormalities were present in 10 % of cases (monosomy 7, one case, monosomy 20,one case, and 1p+, one case). The most common structural chromosomal abnormalities were t(8;21) in 3 cases (10%), t(15;17) in 3 cases (10%), followed by t(16;16) in 1 case (3.3%).This means that 29/30 cases were either good or intermediate riskcytogeneticswhile only one case lies in poor risk cytogenetic (-7).
Lower HOXA9 expression was the best predictor of overall/ disease-free survival and response to therapy. 16 However this appears to reflect certain category of patients in certain population.
CONCLUSION
From the previous study, we can conclude thatHOXA9 was absent in our randomly selected patients.This may be related to geographical distribution. Further study was recommended on wider scale of patients with special stress on bad prognostic category and in those harboring t(7;11)-associated leukemias.
